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Background. Macrophages are of great importance in the development of obesity and psoriasis. Signaling via PPAR-γ in certain
macrophage populations is associated with M2-like features and anti-inflammatory profile. In this research, we evaluated the
anti-inflammatory action of pioglitazone by the immunohistochemical study of M1 and M2 macrophages in psoriasis-affected
skin in obese patients. Methods. We used immunohistochemistry to characterize CD68+ and CD163+ macrophages and
pathomorphological description of skin biopsy, obtained from 6 obese psoriatic patients before and after treatment with 15, 30,
and 45mg pioglitazone, once a day during 6 months. Two patients with conventional therapy and without pioglitazone served
as control. Results. Generally, CD163+ cell quantities in psoriasis-affected skin significantly dominated over CD68+ before and
after all treatment regiments. Among patients who received pioglitazone, some of them clearly responded to treatment from
lowest to highest doses by decreasing CD68+ cells. In the group with 30mg pioglitazone regiment, we detected a significant
reduction of CD68+ cells in dermal infiltrates: CI 95% (16–32) before versus CI 95% (2–7) after treatment. Pioglitazone dose
escalation led to certain normalization of skin morphology. Conclusion. The immunohistochemical study allows us to show the
anti-inflammatory effect of pioglitazone in psoriatic obese patients, which can be mediated by reducing the number of СD68+
macrophages, but not СD163+ macrophages, in the affected dermis.
1. Introduction
Psoriasis is a life-long, incurable, disfiguring, disabling, stig-
matizing disease with a worldwide prevalence of about 2%
[1]. It can manifest in many different forms and often accom-
panied by obesity [2].
The etiology and pathogenesis of psoriasis include many
immunological mechanisms [3, 4], in which macrophages
(Mφs) and their different populations are involved in the
inflammatory cascade [5]. Сomorbid obesity further compli-
cates immunological disorders in psoriasis [2, 6].
The clinical studies showed the therapeutic effects of
PPAR-γ-agonist pioglitazone (PGZ) in the treatment of cuta-
neous and metabolic pathologies in psoriasis [7, 8], but mech-
anisms of such effects remain unclear. PGZ is a specific agonist
of PPAR-γ from the thiazolidinedione group, in which PPAR-
γ stimulation led to a reduction in the expression of NFκB in
mononuclear cells [9]. Macrophages PPAR-γ can be one of
the possible targets for PGZ [10].
In addition, Mφs are of great importance in the develop-
ment of obesity and psoriasis. Accumulated researches
showed that pathogenesis of obesity and psoriasis has a com-
mon trait that causes a systemic inflammatory response.
Excessive accumulation of adipose tissue, which produces
adipokines and cytokines, is a source of chronic inflamma-
tion due to the involvement of macrophages capable of
secreting and activating cytokines for inflammation. It is
proved that fatty tissue has almost all known Toll-like recep-
tors (TLRs). TLR ligands are both LPS of microorganisms
and saturated fatty acids. Activation of fatty tissue TLRs leads
to increased synthesis of adipokines, cytokines, and chemo-
kines and stimulates the subsequent expression of TLRs
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[11]. Molecular mechanisms of chronic systemic inflamma-
tion are associated with proinflammatory nuclear transcrip-
tion factor NFκB [12] and anti-inflammatory activity of
PPARs, which directly modulate the activity of genes respon-
sible for the condition and function of adipose tissue, lipid
metabolism, the activity of inflammatory cells, and their pro-
duction of cytokines, adhesion factors, cell differentiation,
and apoptosis. PPAR-activated receptors are central between
lipids and inflammation because lipids that stimulate chronic
inflammation are PPAR-activating ligands also [13].
There are two main clinically significant subpopulations
of Mφs: classically (M1) and alternatively activated (M2)
[10, 14]. M1 and M2 Mφs have the ability to exhibit the
polar-opposite M2/heal and M1/kill functions [15]. Mφs
polarization occurs against the background of significant
metabolic changes [10]. In different diseases, the M1/M2
ratio can change, as does the expression profile of these cells,
which has a pathogenic role [16, 17].
PPAR-γ tickling of these subpopulations may lead to the
development of anti-inflammatory effects [18–20].
CD68 and CD163 are used to identify Mφs in tissue sec-
tions [21]. CD163 is a hemoglobin-haptoglobin complex-
binding scavenger receptor and one of several macrophage
markers classified as markers of alternatively activated
Mφs [22]. CD68 molecule is functionally important for
M1 macrophages. As a receptor for oxidized low-density
lipoproteins, it can activate M1 phagocytosis and promote
proinflammatory cytokine production. CD68 is highly
expressed on human monocytes and tissue Mφs [21, 23].
The previous study demonstrated that macrophage marker
CD68 was increased in psoriasis compared to normal skin,
and coexpressed with CD163 [24].
Thus, in this research, we evaluated the anti-inflammatory
action of pioglitazone by the immunohistochemical study of
M1 and M2 Mφs in psoriasis-affected skin.
2. Materials and Methods
2.1. Subject Recruitment. Prior to the study, the approval
from the Academy’s Bioethics Commission was obtained.
The study included 8 patients with the verified diagnosis
of extensive psoriasis vulgaris, advanced stage, and moderate
severity with concomitant obesity 30 ≤ BMI < 40 kg/1:73m3
(3 women and 5 men, aged from 40 to 60, the average age
of 52 years). All patients signed a voluntary informed consent
to participate in the study.
Patients were stratified and randomized 1 : 1 : 1 : 1; each
group included 2 patients. The 1st group of patients received
standardized conventional therapy—sedation, detoxifying
agents, antihistamine, hepatoprotectors, vitamins, and 1-2%
salicylic ointment 2 times a day topically. Patients of groups
2, 3, and 4 were prescribed pioglitazone at a dose of 15, 30,
and 45mg, respectively, orally once a day for 28 days, addi-
tionally to the treatment protocol.
2.2. Punch Biopsy. We conducted an in-depth descriptive
study of macrophage subpopulations on skin biopsies. The
samples were obtained by punch biopsy of psoriatic plaques
from the skin areas of lower extremities exactly before treat-
ment and on the 28th day. Punch biopsy was performed
using a special tubular scalpel (Dermo-punch) with a diame-
ter of 3mm, under local infiltration anesthesia with lidocaine
hydrochloride 2%. The biopsies were fixed in a 10% solution
of neutral buffered formalin and embedded in paraffin.
2.3. Immunohistochemical Studies. We performed immuno-
histochemical studies using the streptavidin peroxidase
method. Paraffin sections, 3μm thick, were deparaffinized
and dehydrated, antigens were recovered in citrate buffer in
the microwave oven, and endogenous peroxidase was blocked.
Further, the sections were incubated at 4°C overnight with
murine monoclonal antibodies anti-CD68 (1 : 30, clone PG-
М1, REF PD M065-S, Diagnostic BioSystems, USA) and
anti-CD163 (1 : 100, clone 10D6, REF Mob460-01, Diagnos-
tic BioSystems, USA). Afterwards, the sections were treated
in two steps with the Mouse/Rabbit PolyVue™ HRP/DAB
Detection System (Diagnostic BioSystems, USA), with visual-
ization by chromogen; the nuclei were counterstained with
Mayer’s haemalaun and enclosed under the cover glass. We
used Antibody Diluent buffer as a negative control instead
of primary antibodies, and lymph node tissues were used as
a positive control.
Quantitative indicators were obtained by counting
immunopositive CD68+ and CD163+ cells over the entire
field of view with a large magnification lens ×40 (high power
field, HPF) of the dermal region. We took into account all
obtained quantitative individual data from all fields of view
without calculating the mean. Microphotographs were
obtained using the ZEISS Axio Lab.A1 microscope, Carl
Zeiss MicroImaging GmbH (mg; ×200, ×400).
2.4. Statistical Analysis. We conducted that the statistical
analysis of comparisons between groups was performed
using the GraphPad Prism 5 software with parametric T-
test (if normal distribution) and nonparametric methods:
Wilcoxon rank data analysis for dependent variables and
Spearman correlation.
3. Results
The pathomorphological pattern of the psoriasis-affected
specimens in all patients had characteristic signs of this
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Figure 1: Pathomorphology of psoriasis-affected skin: Munro’s
microabscesses (1), dilated capillaries in the dermal papillae (2),
and lymphohistiocytic infiltrate (3). Hematoxylin-eosin staining,
mg, ×200. Scale bar, 0.5μm.
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disease. We detected the typical changes of the epidermis,
such as accumulation of neutrophils in the stratum corneum
of the epidermis: Munro’s microabscesses, decreased thick-
ness of the epidermis as compared to the length of dermal
papillae, regular acanthosis, often with dentate ridges of the
epidermis, and dilated capillaries in the papillae. Lymphohis-
tiocytic infiltrates of various densities were localized subepi-
dermally in the dermal papillae (Figure 1).
In psoriatic skin lesions, general characteristics of CD68+
and CD163+ were as follows: immunoreactivity was
observed in the form of brown granular staining of cells,
which revealed their different size and shape features; CD68
+ and CD163+ cells in psoriatic skin were localized in the
dermal papillae and deeper dermis, along and around the
dilated superficial vessels, as well as in the composition of
lymphohistiocytic infiltrates. We found the largest number
of immunopositive cells in the papillary and reticular layers
of the dermis (Figures 2–4).
Visually, the number of CD163+ cells dominated in all
samples. The assessment of CD68+/CD163+ ratio, obtained
by the T-test for dependent variables, confirmed a signifi-
cantly higher fraction of CD163+ cells (p = 0:0002), with no
significant correlation between CD68+ and CD163+ quanti-
ties. The average number of CD68+ was 10 cells (per HPF of
papillary and reticular layers of dermis), confidential interval
(CI) 95% (6–14), whereas the number of CD163+ was 22
cells, CI 95% (17–26).
After treatment, the ratio did not change, and CD163+
Mφs prevailed over CD68+ (p = 0:0002, Wilcoxon method)
in all groups.
Numerous CD163+ cells in psoriasis were observed in at
least two forms: small-sized cells with a small nucleus, as in
lymphocytes, and relatively large branched cells; these varie-
ties persisted after treatment. Both types of cells were local-
ized in essentially the same areas and had different shapes
depending on the position. Hence, the slightly larger ones
were on the tips of the papillae, whereas smaller cells were
in the composition of lymphohistiocytic infiltrates, and/or
flattened spindle-shaped—in the reticular layer. The typical
localization was along the vessels of the dermal papillae,
which were observed specifically for CD163+ cells, where
they formed a kind of the first line (Figure 2), as compared
to CD68+ (Figure 3). CD68+ Mφs also occurred in different
shapes and sizes, slightly sparse in infiltrates, and presented
in the dermal papillae, sometimes not in all, around the cap-
illaries (Figure 4).
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Figure 2: Immunohistochemical detection of CD163+ cells in the psoriatic plaque biopsy specimen before (a) and after treatment with 30mg
pioglitazone (b). CD163+ cells (arrows) are rather tightly represented in the dermal papillae surrounding the vessels. Contrasting: Mayer’s
haemalaun, mg, ×400. Scale bars, 0.2 μm. CD163+ сell number in all groups did not differ significantly before and after treatment (c).
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The morphological and quantitative comparison of
CD163+ cells before and after treatment demonstrated no
significant differences in each group and in total (Figure 2).
In the group with conventional therapy, comparison of
CD68+ cells before and after treatment demonstrated no sta-
tistically significant changes or morphologic differences (p =
0:343, data not shown).
A personalized approach justifies close attention to each
patient. Therefore, the study revealed the patient who clearly
responded to the treatment with the 15mg of PGZ, in whom
CD68+ cells almost completely disappeared after treatment.
In the group with 30mg PGZ, the statistical comparison
of CD68+ cells (Wilcoxon method) showed a significant
decrease. Treatment with 30mg PGZ use decreased the num-
ber of CD68+ cells from CI 95% (16–32) to CI 95% (2–7) sig-
nificantly (Figure 3).
Besides, in one patient after the treatment with 45mg of
PGZ, dermal papillae presented on the preparation were
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Figure 3: Immunohistochemical detection of CD68+ cells in psoriatic plaque biopsy specimens. (a) CD68+ cells (arrows) in the infiltrate and
the reticular layer of the dermis before treatment. (b) Single CD68+ cells (arrow) after the treatment with 30mg pioglitazone. Contrasting:
Mayer’s haemalaun, mg, ×400. Scale bars, 0.2 μm. (c) CD68+ cells reduced significantly (Wilcoxon method).
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Figure 4: Immunohistochemical detection of CD68+ cells in skin biopsy specimens after treatment of psoriasis with pioglitazone 45mg. (a)
Single immunopositive cell (1) and granular layer (2). Contrasting: Mayer’s haemalaun, mg, ×400. Scale bar, 0.2 μm. (b) CD68+ сell number
in the patient did not differ significantly.
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smoothed, epidermal ridges were rounded, and orthokerato-
sis (morphological signs of some normalization of the skin
condition) and only single CD68+ cells were observed, which
can be interpreted as a decrease in the infiltration density
(Figure 4).
4. Discussion
The involvement of Mφs in the pathogenesis of psoriasis is a
long-standing but actual research issue. In psoriasis, Mφs are
involved in the perception of danger signals. Their activation
by the proinflammatory cytokines IL-6 and TNF-α and che-
mokines CXCL8, CCL5, CXCL1, and CXCL2 involves other
inflammatory cells [25]. It is known that the number of Mφs
increases significantly in psoriasis-affected tissues [26]. The
M1/M2-type macrophages drove T cell differentiation to
Th1- or Th2-like phenotype, respectively. Such macrophage-
innate activities are the central directing element in immune
responses which is a drastic change in understanding how
immune systems operate. Most importantly, this revelation
is opening up whole new approaches to immunotherapy [27].
The data on Mφs polarization under the influence of
PPAR-γ agonists and antagonists are steadily growing,
mainly in animal models [18-20]. Signaling via PPAR-γ in
the individual Mφs populations is associated with M2-like
features, including the anti-inflammatory ones [28].
Thus, we investigated the influence of PPAR-γ agonist
PGZ on M1 and M2 Mφs of psoriasis-affected skin, by
immunohistochemical study. Our data showed a decrease
in the CD68+ Mφs population by different doses of PGZ.
CD68 marker was used in a recent study as one of the iden-
tifiers for inflammatory M1 [29]. The reduction of CD68+
Mφs has correlated with clinical success in psoriatic
patients. The numbers of phosphorylated IκBα activated
CD68+ Mφs were reduced in psoriasis plaques after treat-
ment with new biomaterials based on nanoparticles signifi-
cantly [29]. Therefore, a decrease of CD68+ M1 can explain
the success of PGZ treatment.
In obese psoriatic patients, CD163+ cells were the pre-
dominant population in the affected skin, compared to
CD68+. Conventional treatment did not influence this ratio.
The prevalence of CD163+ cells as alternative activated
Mφs goes in parallel with angiogenesis de novo in psoriatic
skin. The descriptive morphological comparison of CD163+
cells before and after the treatment with PGZ showed no
drastic changes.
Our data support the idea that CD163+ cells drive
immune-mediated proliferation in these patients [30]. On
the other hand, the controversial data about CD163+ cell
classical activation in psoriasis were published [24].
PPAR-γ-dependent activation of macrophages is obvi-
ously capable of restoring the vital cleaning or clearance
functions of macrophages in some infections, preventing
excessive inflammation in septic conditions [28]. Therefore,
the administration of PGZ may also influence CD163+ M2
Mφs, although their quantitative and morphological changes
could not be recorded in this study.
Additional treatment with PGZ reduced the number of
CD68+ cells starting at a dose of 15mg; statistical significance
was registered at a dose of 30mg. Furthermore, in the
dose of 45mg, there were also signs of the decreased density
of CD68+, together with morphological manifestations of
regression of psoriatic plaques: thickening of the epidermis,
orthokeratosis, reduced height of the dermal papillae, and
lack of branching of the epidermal ridges. Thus, PGZ dose
escalation led to certain normalization of skin morphology.
CD68 is a type I integral membrane protein with a
heavily glycosylated extracellular domain and binds to tissue-
and organ-specific lectins or selectins. The protein is a mem-
ber of the scavenger receptor family, with typical functions
which are cellular debris removal, phagocytosis promotion,
and Mφs recruitment. Thus, СD68 contributes to inflamma-
tion support [31].
Taken together with clinical indicators in the dynamics of
psoriasis treatment with PGZ, such as a decrease of PASI
index and reduction of relapse rate up to 1-2 times per year
[7, 8, 32], decreasing of CD68+ cells indicates inhibition of
inflammation locally.
The limitations of the study were a small number of
patients due to ethical reasons and using of Mφs markers that
can partially overlap in pathology [16, 17, 24, 29].
Further research will be targeted on the investigation of
M1/M2 cytokine levels under PGZ influence on obese psori-
atic patients.
5. Conclusions
The immunohistochemical study allows us to show the anti-
inflammatory effect of pioglitazone in psoriatic obese
patients, which can be mediated by reducing the number of
СD68+ macrophages, but not СD163+ macrophages, in the
affected dermis.
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